Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615653 · ClinicalTrials.gov registry record · NA
EUS Guided Celiac Neurolysis
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01615653: Completed NA study, sponsored by Mayo Clinic.
NCT01615653 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01615653, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
* Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.
Primary Outcome
pain response will be measured
Interventions
- PROCEDURE EUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT01615653 record still lists
NCT01615653 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which EUS is the first listed.
NCT01615653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01615653 about?
NCT01615653 is a clinical study titled "EUS Guided Celiac Neurolysis". * Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid disper...
What is the current status of trial NCT01615653?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2009-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01615653?
The interventions under investigation include: EUS (PROCEDURE).
Who is sponsoring clinical trial NCT01615653?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01615653's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia